Petra Acquisition Inc.: management transactions · United States · SEC (Form 4)

About Petra Acquisition Inc.

Petra Acquisition Inc. was a U.S.-listed SPAC that traded on Nasdaq, making it relevant to investors who track SEC filings and, in particular, insider activity reported on Form 4. The company was incorporated in Delaware on November 20, 2019, and its principal executive office was listed in New York City at 5 West 21st Street, New York, NY 10010. From inception, Petra was not built as a traditional operating business. Its purpose was to identify and complete a business combination such as a merger, share exchange, asset acquisition, stock purchase, recapitalization, or similar transaction with a private company. In its IPO materials, Petra stated that it would pursue a business combination without being limited to a single industry, although the original focus was on healthcare and healthcare-related businesses. That sector emphasis is important because it provides context for the type of acquisition target the sponsor likely intended to pursue. Like most SPACs, Petra’s value proposition was structural rather than operational: it offered a public-market listing vehicle, cash held in trust, and a faster alternative to a conventional IPO for a target company seeking access to capital markets in the United States. Petra raised gross proceeds of $70 million in its initial public offering, with units consisting of one share and one warrant. The company’s competitive position should therefore be understood relative to other U.S. SPACs rather than against product-driven operating peers. Its differentiation depended on sponsor quality, transaction sourcing, financing structure, and the ability to complete a credible merger within the required timeframe. In that sense, Petra’s market position was typical of a sponsor-led blank-check vehicle: it competed for attractive private targets in a highly regulated environment overseen by the SEC and the public markets. Geographically, Petra was a U.S. company with a Delaware charter and a New York executive base. Its market presence was financial and regulatory, centered on Nasdaq and SEC disclosure. The most significant recent milestone in its corporate history was the completion of its business combination with Revelation Biosciences on January 10, 2022, after which Petra changed its name to Revelation Biosciences, Inc. This means that historical references to Petra Acquisition Inc. should generally be read as references to a pre-combination SPAC rather than a standalone operating company. For investors, the key analytical takeaway is that Petra Acquisition Inc. should be assessed through the lens of SPAC mechanics, deal execution, governance, and post-merger transition rather than through revenue, margins, or product commercialization. In a Form 4 context, the focus is on insider disclosures and the corporate actions around and after the combination event.